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Background: Pelubiprofen is a prodrug of 2-arylpropionic acid with relatively selective effects on cyclooxygenase-2
activity. The aim of this study was to compare the efficacy and safety profiles of pelubiprofen with those of celecoxib in
patients with rheumatoid arthritis.
Methods: This was a 6-week, multicenter, randomized, double-blind, double-dummy, parallel-group, phase III,
non-inferiority clinical trial. The primary end point was non-inferiority of pain decrease from baseline to week-6 as
determined using a 100 mm pain visual analog scale (VAS). Pelubiprofen was considered non-inferior to celecoxib if
the lower limit of the 97.5% confidence interval for treatment difference [(pain reduction in pelubiprofen group) – (pain
reduction in celecoxib group)] was more than −10 mm. The secondary end points were as follows: non-inferiority of
(1) reduction of Korean health assessment questionnaire (KHAQ) score; (2) decreased duration of morning stiffness; and
(3) decrease in the frequency and total dose of rescue drugs after 6 weeks of treatment.
Results: Seventy-seven patients in the pelubiprofen group and 68 patients in the celecoxib group started the study
medication. Pelubiprofen was non-inferior to celecoxib with regard to reduction in VAS pain severity (difference,
mean ± SD 5.0 ± 20.1; 97.5% CI, −2.3 to ∞). Pelubiprofen was also non-inferior to celecoxib in terms of the secondary
end points, such as, decrease in KHAQ score (0.0 ± 0.5, 97.5% CI −0.2 to ∞), decrease in duration of morning stiffness
(median 0.0 minute in both groups), and decrease in the frequency (0.7 ± 3.5, 97.5% CI −0.6 to ∞) and total amount
(0.7 ± 3.6, 97.5% CI −0.6 to ∞) of rescue medication uses during the 6 week study period. Safety analysis revealed 31.2%
patients in the pelubiprofen group and 20.6% patients in the celecoxib group experienced an adverse drug reaction
(ADR). The frequency of gastrointestinal ADRs was 20.8 % and 8.8%, respectively.
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Conclusions: Pelubiprofen was found to be as effective as celecoxib at pain reduction and for relieving stiffness in RA
patients. However, more patients in the pelubiprofen group experienced ADR and the frequency of gastrointestinal
ADRs was higher in the pelubiprofen group. ClinialTrials.gov identifier: NCT01781702.
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Rheumatoid arthritis (RA) is a chronic inflammatory
arthritis and often results in joint damage and physical
disability. Nonsteroidal anti-inflammatory drugs (NSAIDs)
alleviate pain and stiffness and are widely used to con-
trol the symptoms of RA. Patients tend to take multiple
medications including corticosteroids, NSAIDs, and
disease-modifying anti-rheumatic drugs (DMARDs).
However, the long-term use of NSAIDs is frequently
limited by gastrointestinal (GI) adverse effects, such as,
dyspepsia, abdominal pain, gastric ulcers, and bleeding
[1,2]. Cyclooxygenase (COX)-2 selective inhibitor was
developed to improve this unsatisfactory profile of
NSAIDs and its use is common in the elderly and in
those who are at risk of GI bleeding, including patients
with RA [3-5].
Pelubiprofen is a member of the 2-arylpropionic acid
family, which is related structurally and pharmacolo-
gically to ibuprofen. Pelubiprofen is known to inhibit
COX activity and the transforming growth factor-β
activated kinase 1 - IκB kinase β - NF-κB pathway [6],
and in clinical studies was found to have significant
anti-inflammatory and analgesic effects [Gu-youn Kwon:
Phase II and III clinical study report of pelubiprofen
(DW-330), Daewon Pharm, data unpublished]. The
Korean Ministry of Food and Drug Safety approved
pelubiprofen for relieving the symptoms of osteoarth-
ritis (OA) in 2007 and approved expanded indications
for the relief of symptoms of back pain in 2010. This
phase III trial was designed as a part of new drug appli-
cation to expand the indications of pelubiprofen for
relieving the symptoms of RA.
Pelubiprofen is believed to cause fewer GI adverse
events than traditional NSAIDs because it is a prodrug.
In addition, it has selective effects on COX-2 activity
(COX-1/COX-2 ratio: 3.7) [6]. Therefore, we expected
pelubiprofen to be useful at relieving the symptoms
of RA in patients at high risk of an adverse GI event.
The objective of this trial was to compare the efficacy
and safety profiles of pelubiprofen with those of cele-
coxib in patients with moderate to severe RA. In the
current study, we tested the hypothesis that pelubipro-
fen would be non-inferior to celecoxib in terms of
pain reduction, improving quality of life, reducing
morning stiffness and overall safety in patients with
moderate to severe RA.Methods
Patients
Participants were all Korean, aged 18 to 80 years, and
taking NSAIDs for the treatment of RA. All satisfied the
1987 American College of Rheumatology (ACR) classifi-
cation criteria of RA [7], and had a disease duration of
over 3 months and an ACR functional class of I, II or III
[8]. Furthermore, all had been taking stable doses of
DMARDs, such as, methotrexate, sulfasalazine, hydroxy-
chloroquine, or leflunomide for over 3 months at the
screening visit and maintained these doses during the
study period. A stable low dose of prednisolone at
10 mg or less per day over 4 weeks was permitted. On
randomization, patients were required to have worsened
pain, defined as an increase in pain visual analog scale
(VAS) score at least 10 mm or of 20% from baseline dur-
ing the washout period, and to have moderate or severe
arthritis, which was defined as a disease activity score of
28 (DAS28) ≥3.2.
Patients were excluded if they had a history of hyper-
sensitivity to NSAIDs or a serious cardiovascular, liver,
kidney or blood disease or another autoimmune disease.
Those with a peptic ulcer or GI bleeding confirmed by
endoscopy or radiography within 6 months of enrollment
or who could not discontinue their GI medication, such
as, H2 blocker, misoprostol or proton pump inhibitor were
excluded. Patients were also excluded if they had been
treated with intra-articular corticosteroid within 4 weeks
prior to screening or had previously been administered
biologic DMARDs, such as, infliximab, adalimumab,
etanercept, anakinra, or abatacept within 6 months or
rituximab within 1 year of enrollment. Pregnant women,
breastfeeding women, and women of childbearing poten-
tial not using an appropriate method of contraception,
such as, condoms, intrauterine devices, and oral contra-
ceptives, were excluded.
Study procedure
This was a 6-week, multicenter, randomized, double-blind,
double-dummy, parallel-group, phase III, non-inferiority
clinical trial conducted at 14 medical centers in Korea from
October 2010 to October 2011. The study protocol was
approved by the Institutional Review Boards at each of the
participating institutes, which were; Seoul National Univer-
sity College of Medicine-Seoul National University Hospital
Institutional Review Board (IRB), Gachon University Gil
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Yeouido St. Mary's Hospital Catholic IRB, Kyung-Hee
University Hospital IRB, Dong-A University Hospital IRB,
Pusan National University Hospital IRB, Severance Hospital
IRB, Ewha Womans University Medical Center IRB,
Chonnam National University Hospital IRB, Chonbuk
National University Hospital IRB, Chung-Ang University
Hospital IRB, Chungnam National University Hospital
IRB, and Hallym University Sacred Heart Hospital IRB.
Written informed consent was obtained from each patient
before study enrollment. No important change to study
methods was made after trial commencement.
Study medications and comparators were packed in
identical appearance and consecutively numbered accord-
ing to the allocation sequence. Random allocation sequence
generated using SAS 9.1v software (SAS Institute, Cary,
NC) by an independent statistician and was stratified by
center with a 1:1 allocation using random block sizes of
4 and 6. After a 3–14 day washout period depending on
the half-lives of NSAIDs, patients who experience pain
worsening were assigned order numbers by investigators
at each center and received the corresponding medication
from pharmacists. A double-dummy design was imple-
mented because the pelubiprofen tablet and celecoxib
capsule differed in appearance and dosage. Patients in
pelubiprofen group received a pelubiprofen 30 mg tablet
three times daily and a celecoxib placebo capsule twice
daily. Patients in celecoxib group received a 200 mg
Celebrex® capsule twice daily and pelubiprofen placebo tab-
let three times daily. The allocation sequence was concealed
from the researcher enrolling and assessing participants
and who kept randomization envelopes. The sponsor and
the principal investigators at each center were in charge of
the envelopes, which were opaque, sealed, and not opened
until trial completion. Blinding could only be broken in
emergency situations for reasons of patient safety.
The drug administration period was 6 weeks. During
weeks 0, 2 and 4, participants were given sufficient study
medication to last until their next scheduled visit plus
an additional amount to accommodate visits scheduled
within the allowed visit variance (±4 days), and were
asked to return all unused medication during visits on
weeks 2, 4, and 6. Compliance with study medication
was monitored by noting returned medication on case
report forms. Rescue medication was allowed in the form
of an acetaminophen extended-release (ER) 650 mg tablet.
The total amount of rescue medication used was tracked
using an accountability procedure.
Efficacy and safety profiles
The primary end point was pain decrease from baseline
to week 6 as determined using a 100 mm pain VAS.
Patients specified general pain experienced during the
previous 48 hours by indicating a position along acontinuous line between the two end-points (0 mm = no
pain and 100 mm = severest pain imaginable) under the
supervision of the study investigator [9]. Changes in VAS
pain from week 0 to 6 in the two groups were compared
using the t-test and are presented with 97.5% confidence
intervals (CI). We hypothesized that pelubiprofen was
non-inferior to celecoxib if the lower limit of the 97.5%
confidence interval for the treatment difference [(pain
reduction in pelubiprofen group) – (pain reduction in
celecoxib group)] was more than −10 mm. Secondary end
points were as follows: (1) reduction of Korean health
assessment questionnaire (KHAQ) score; (2) decreased
duration of morning stiffness; and (3) decrease in the
frequency and total dose of rescue drugs after 6 weeks of
treatment.
Differences in the duration of morning stiffness between
baseline and week 6 were calculated and presented in
median. Duration of morning stiffness is reported in
minutes and durations of more than 360 minutes are
reported as 360 minutes. The KHAQ consisted of 20
items in 8 categories that addressed; (1) dressing and
grooming, (2) arising, (3) eating, (4) walking, (5) hygiene,
(6) reach, (7) grip, and (8) common daily activities. For
each of these categories, patients reported the amount of
difficulty experienced when performing 2 or 3 items using
a 4 score: 0 = without any difficulty, 1 = with some diffi-
culty, 2 = with much difficulty, and 3 = unable to do. A
category score was determined using the highest score of
the items in that category. The sum of all category scores
was then divided by the number of categories answered to
produce a single disability index score [10,11]. Usages of
rescue medication were assessed at baseline and on treat-
ment weeks 2, 4, and 6 and analyzed for frequencies and
amounts of acetaminophen ER 650 mg tablets used during
the previous 2 weeks by repeated measure analysis of vari-
ance (ANOVA). All the other efficacy assessments were
performed at baseline and week 6.
The investigators, who were blinded to treatment group
identities, described and assessed all clinical and labora-
tory adverse events (AEs). Clinical AEs were evaluated by
physical examination and general questioning at every
visit, and laboratory AEs were evaluated by complete
blood count, serum chemistry and urinalysis at screening
and last visit (week 6). All AEs were categorized according
to the likelihood of a causal relationship with the study
drug, that is, as definitely related, probably related, pos-
sibly related, probably not related, definitely not related,
or unknown [12]. Causal relationships of AEs were deter-
mined based on clinical judgment by the investigators.
Adverse drug reactions (ADRs) were defined as AEs that
were at least possibly related to study medications. Serious
AEs and ADRs were defined as those associated with any
of the following: death; an event associated with a high
risk of mortality; an event requiring hospitalization; or
Table 1 Baseline characteristics of patients with
rheumatoid arthritis treated with pelubiprofen or celecoxib
Variable Pelubiprofen
(n =77)
Celecoxib
(n =68)
Age (mean ± SD, year) 54.3 ± 11.4 54.8 ± 10.8
Female sex, no. (%) 69 (89.6) 62 (91.2)
Disease duration (mean ± SD, month) 100.2 ± 104.2 89.8 ± 88.1
ACR functional class
Class I, no. (%) 25 (32.5) 24 (35.3)
Class II, no. (%) 45 (58.4) 40 (58.8)
Class III, no. (%) 7 (9.1) 4 (5.9)
Class IV, no. (%) 0 (0.0) 0 (0.0)
DMARD use, no. (%) 55 (71.4) 47 (69.1)
Prednisolone use, no. (%) 54 (70.1) 42 (61.8)
ACR, American College of Rheumatology; DMARD, disease-modifying
anti-rheumatic drug.
P values were determined using the Student t-test or the χ2 test.
Figure 1 Patient allocation, follow-up, and analysis in the study of pe
arthritis. aExcluded from safety analysis. a+bExcluded from intention to trea
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malformation.Statistical analyses
Baseline patient characteristics in the pelubiprofen and
celecoxib study groups were analyzed. Continuous vari-
ables are expressed as means ± standard deviations (SD),
and categorical variables as numbers and percentages.
For the sample size calculation, we referred to the
report of Song et al. [13]. In this non-inferiority trial using
celecoxib, reduction in 100 mm VAS pain was 17.87 mm
and its SD was 19.06 mm. Based on the non-inferiority
margin of −10 mm reported, pelubiprofen was considered
non-inferior to celecoxib if the lower limit of the 97.5% CI
of treatment difference [(pain reduction in the pelubipro-
fen group) – (pain reduction in the celecoxib group)] was
more than −10 mm. With a 1-sided significance level of
0.025 and assuming a SD of 19.06 mm, a sample size of 58
patients per group was determined to provide a study
power of 80%, and thus, 73 patients were deemed to be
required given a 20% dropout rate. Secondary outcomes
were also tested for non-inferiority using one-sided tests.lubiprofen versus celecoxib for the patients with rheumatoid
t analysis.
Figure 2 Mean pain intensity in patients with rheumatoid
arthritis treated with pelubiprofen 30 mg t.i.d. or celecoxib
200 mg b.i.d. as measured using a 100 mm visual analog scale
(VAS). Bars represent standard deviations.
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ulations were used for the main analysis and intent-to-
treat (ITT) populations were used for supplementary
analysis with the input of any missed observations ac-
cording to the last observation-carried-forward method.Table 2 Per protocol analysis of primary and secondary end p
Variable Pel
30
Patient’s pain VAS, 0–100 mm, mean (SD)
Week 0 69.1
Week 6 42.9
Difference (Week 0 – Week 6) 26.2
KHAQ, mean (SD)
Week 0 1.0
Week 6 0.8
Difference (Week 0 – Week 6) 0.2
Duration of morning stiffness, min, median
Week 0 30.0
Week 6 10.0
Difference (Week 0 – Week 6)* 0.0
Frequency of rescue medication, times in last two weeks, mean (SD)
Week 0 2.8
Week 6 1.4
Difference (Week 0 – Week 6) 1.4
Total dose of rescue medication, tablets in last two weeks, mean (SD)
Week 0 3.0
Week 6 1.6
Difference (Week 0 – Week 6) 1.4
SD, standard deviation; CI, confidence interval; VAS, visual analog scale; KHAQ, Kore
*p =0.99 by Wilcoxon’s rank sum test.The safety population included all patients who had
received ≥1 dose of study medication after randomization
and incidences of AEs and of ADRs in the study groups
were compared using the χ2 test or Fisher’s exact test. The
ITT population included all patients who had received ≥1
dose of study medication after randomization and were
available for analysis of the primary end point. The PP
population included only those patients who had com-
pleted the protocol at the end of the study period.
Protocol violators and patients with <80% drug compli-
ance were excluded from the PP analysis. Statistical
analysis was conducted using SAS version 9.1 (SAS
Institute Inc., Cary, North Carolina). Statistical signifi-
cance was accepted for p values <0.05.
Results
Patient characteristics
Of the 172 patients assessed for eligibility, 149 satisfied
the inclusion/exclusion criteria and were randomly
allocated to the pelubiprofen group (79 patients) or the
celecoxib group (70 patients). Seventy-seven patients in
the pelubiprofen group and 68 patients in the celecoxib
group received at least 1 dose of study medication and
were included in the safety population. Baseline charac-
teristics of the two groups are summarized in Table 1.oints
ubiprofen
mg (n =62)
Celecoxib
200 mg (n =58)
Difference
Mean (SD) 97.5% CI, one-sided
(17.2) 64.0 (19.3)
(21.4) 42.7 (24.2)
(19.5) 21.2 (20.8) 5.0 (20.1) −2.3, ∞
(0.7) 1.0 (0.7)
(0.7) 0.8 (0.7)
(0.5) 0.2 (0.5) 0.0 (0.5) −0.2, ∞
30.0
15.0
0.0
(4.0) 2.2 (3.2)
(2.9) 1.5 (3.4)
(3.7) 0.7 (3.4) 0.7 (3.5) −0.6, ∞
(4.0) 2.2 (3.2)
(3.1) 1.5 (3.6)
(3.6) 0.7 (3.5) 0.7 (3.6) −0.6, ∞
an health assessment questionnaire.
Table 3 Adverse events that occurred during the study
Pelubiprofen (n =77) Celecoxib (n =68)
Patients, n (%) Events, n Patients, n (%) Events, n p-value*
Total adverse events 39 (50.6) 62 25 (36.8) 33 0.09
Gastrointestinal 21 (27.3) 29 7 (10.3) 8 0.01
Anorexia 2 (2.6) 2 1 (1.47) 1
Nausea 2 (2.6) 3 3 (4.41) 3
Vomiting 1 (1.3) 1 1 (1.47) 1
Indigestion 3 (3.9) 2 1 (1.47) 1
Epigastric discomfort 4 (5.2) 4 0 (0.0) 0
Abdominal pain 10 (13.0) 10 2 (2.94) 2
Diarrhea 4 (5.19) 5 0 (0.0) 0
Constipation 2 (2.6) 2 0 (0.0) 0
Systemic 11 (14.3) 13 4 (5.9) 4 0.10
Facial edema 5 (6.49) 5 1 (1.5) 1
Edema 4 (5.19) 5 1 (1.5) 1
Chest discomfort 1 (1.3) 1 0 (0.0) 0
Nipple pain 0 (0.0) 0 1 (1.5) 1
Weight gain 0 (0.0) 0 1 (1.5) 1
Pain 1 (1.3) 1 0 (0.0) 0
Fatigue 1 (1.3) 1 0 (0.0) 0
Anemia 0 (0.0) 0 1 (1.5) 1 0.29
Respiratory 6 (7.8) 6 4 (5.9) 4 0.65
Nervous system 2 (2.6) 2 4 (5.9) 6 0.32
Skin and appendage 3 (3.9) 4 1 (1.5) 1 0.37
Musculoskeletal 1 (1.3) 1 2 (2.9) 2 0.49
Hepatobiliary 1 (1.3) 1 1 (1.5) 2 0.92
Reproductive system 1 (1.3) 1 1 (1.5) 2 0.92
Cardiovascular 1 (1.3) 1 1 (1.5) 1 0.92
Infection 0 (0.0) 0 1 (1.5) 1 0.29
Eye 1 (1.3) 1 0 (0.0) 0 0.35
Urinary 1 (1.3) 1 0 (0.0) 0 0.35
Psychiatric 1 (1.3) 2 0 (0.0) 0 0.35
Peripheral vascular 0 (0.0) 0 1 (1.5) 1 0.29
*p-value by the chi-square test: difference between the proportions of patients that developed an adverse event.
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patient in the celecoxib group dropped out without a
primary end point data, 75 patients in the pelubiprofen
group and 67 patients in the celecoxib group were
included in the ITT population. Overall, 66 patients in
the pelubiprofen group and 64 patients in the celecoxib
group completed the study, and 62 patients in the pelu-
biprofen group and 58 patients in the celecoxib group,
excluding protocol violators and patients with <80%
drug compliance, were finally included in the PP analysis
(Figure 1). No missing data was accommodated in the
ITT analysis.Efficacy profile
Mean decrease ± SD of VAS pain was 26.2 ± 19.5 mm
(range: 0.0-80.0 mm) in the pelubiprofen group and
21.2 ± 20.8 mm (range −20.0–90.0 mm) in the celecoxib
group. The difference between two groups was 5.0 ± 20.1
and the lower limit of the 97.5% confidence interval
was −2.3 mm, which was higher than the non-inferiority
limit of −10.0 mm. Therefore, primary end point analysis
indicated pelubiprofen was non-inferior to celecoxib
(Figure 2). The results of ITT analysis for the primary end-
point were consistent with those of PP analysis (difference,
4.7 ± 20.8; 97.5% CI, −2.2 to ∞).
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was 0.2 ± 0.5 in the pelubiprofen group and 0.2 ± 0.5 in
the celecoxib group (difference, 0.0 ± 0.5, 97.5% CI −0.2
to ∞). Median duration of morning stiffness was decreased
by 0.0 minute in the pelubiprofen group and by 0.0 minute
in the celecoxib group (p =0.99 by Wilcoxon’s rank
sum test). Mean decrease in the frequency of rescue
medication was −1.39 ± 3.68 in pelubiprofen group
and −0.72 ± 3.39 in celecoxib group (difference, 0.7 ±
3.5, 97.5% CI −0.6 to ∞), and mean decrease in the total
use of rescue medication was 1.38 ± 3.58 in pelubiprofen
group and 0.71 ± 3.53 in celecoxib group (difference, 0.7 ±
3.6, 97.5% CI −0.6 to ∞) (Table 2). The results of ITT
analysis for the secondary end point were consistent with
those of PP analysis (data now shown).
Safety profile
Thirty-nine patients (50.6%) reported 62 AEs in the
pelubiprofen group, and 25 patients (36.8%) reported 33
AEs in the celecoxib group (p =0.09, Table 3). Twenty-
four patients (31.2%) in the pelubiprofen group and 14
patients (20.6%) in the celecoxib group experienced 51
ADRs (34 vs. 17 events, respectively, p =0.15, Table 4).Table 4 Adverse drug reactions that occurred during the stud
Pelubiprofen (n =77)
Patients, n (%) Events, n
Total number of patients 24 (31.2) 34
Gastrointestinal 16 (20.8) 20
Anorexia 2 (2.6) 2
Nausea 1 (1.3) 2
Indigestion 2 (2.6) 2
Epigastric discomfort 2 (2.6) 2
Abdominal pain 9 (11.7) 9
Diarrhea 1 (1.3) 1
Constipation 2 (2.6) 2
Systemic 8 (10.4) 10
Facial edema 5 (6.49) 5
Edema 3 (3.9) 4
Weight gain 0 (0.0) 0
Pain 1 (1.3) 1
Respiratory 2 (2.6) 2
Nervous system 0 (0.0) 0
Skin and appendage 0 (0.0) 0
Hepatobiliary 1 (1.3) 1
Reproductive system 1 (1.3) 1
Cardiovascular 0 (0.0) 0
Infection 0 (0.0) 0
Peripheral vascular 0 (0.0) 0
*p-value by the chi-square test: difference between the proportions of patients thatThe most common ADRs were abdominal pain [10/77
(13.0%) in the pelubiprofen group vs. 2/68 (2.9%) in the
celecoxib group, p =0.03]. The frequency of gastrointes-
tinal ADR was higher in the pelubiprofen group (20.8 %
vs. 8.8%, p =0.045). One serious AE was reported in each
group (right femoral neck fracture after trauma resulting
in surgery in the pelubiprofen group and left knee
tendon rupture resulting in surgery in the celecoxib
group). Investigators reported both as being definitely
not related to the study medication.
Discussions
In the present study, pelubiprofen and celecoxib were
compared with respect to analgesic and anti-inflammatory
effectiveness and safety profile. Pelubiprofen was found to
be non-inferior to celecoxib in terms of pain reduction,
improving quality of life, and reducing morning stiffness.
The frequency and usage of rescue medication decreased
in both groups.
However, although pelubiprofen was found to be
non-inferior in terms of efficacy versus celecoxib, its
safety profile was less favorable. Pelubiprofen has been
previously reported to be better tolerated than aceclofenacy
Celecoxib (n =68)
Patients, n (%) Events, n p-value*
14 (20.6) 17 0.15
6 (8.8) 6 0.045
1 (1.47) 1
2 (2.94) 2
1 (1.47) 1
0 (0.0) 0
2 (2.94) 2
0 (0.0) 0
0 (0.0) 0
3 (4.4) 3 0.17
1 (1.5) 1
1 (1.5) 1
1 (1.5) 1
0 (0.0) 0
1 (1.5) 1 0.63
1 (1.5) 1 0.29
1 (1.5) 1 0.29
1 (1.5) 2 0.49
0 (0.0) 0 0.35
1 (1.5) 1 0.29
1 (1.5) 1 0.29
1 (1.5) 1 0.29
developed an adverse event.
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abdominal pain in patients with back pain [14]. However,
in the present study, it was found to have a poorer GI
safety profile than celecoxib in patients with RA in terms
of numbers of GI events and in terms of numbers of
systemic and overall AEs, which were almost twice as
frequent in the pelubiprofen group. Furthermore, this
pattern was similar for adverse drug reactions. How-
ever, mean pain reduction tended to be greater in the
pelubiprofen group (26.2 mm vs. 21.2 mm). Further
study is required to confirm its superior efficacy versus
celecoxib and other non-selective NSAIDs in terms of
pain reduction.
The present study has some limitations that warrant
consideration. First, the study was too short to allow
meaningful evaluations of the long-term AEs associated
with pelubiprofen, especially regarding cardiovascular
events [15]. Accordingly, future studies are required to
evaluate its long term effects. Second, this study was
performed on a selected population and specific inclusion
and exclusion criteria were applied, such as, no concomi-
tant high dose steroids or biologic DMARDs, which are
commonly used to treat moderate to severe RA. In
addition, only patients demonstrating flare after discon-
tinuation of an effective NSAID were included, which is
not optimal for generalizability. Third, the non-inferior
margin of a −10 mm difference for a change in VAS pain
was rather large. However, the intergroup difference
between mean changes in VAS pain was 5.0 ± 20.1 (97.5%
CI, −2.3 to ∞), and accordingly, the primary outcome of
this study could have been achieved even if a stricter
standard had been employed.
In one multi-institution clinical study conducted by
Shin et al. on patients with back pain, it was reported
that the pain reduction afforded by pelubiprofen was not
inferior to that of aceclofenac, which is a non-selective
NSAID [14]. The present study is the first to report that
the analgesic and anti-inflammatory effects of pelubiprofen
are non-inferior to celecoxib in patients with chronic in-
flammatory arthritis. Furthermore, the frequency and usage
of rescue medication also decreased similarly in our pelubi-
profen and celecoxib groups.
Conclusions
Pelubiprofen was found to be as effective as celecoxib
for the pain reduction and for relieving stiffness in mod-
erate to severe RA. The usages of rescue medication
during the 6 week study period were decreased in both
pelubiprofen and celecoxib groups. Furthermore, both
treatments were generally well tolerated, although pelu-
biprofen showed a less favorable GI event profile. The
results of this 6-week trial suggest that both drugs are
effective and sufficiently safe to use in patients with
moderate to severe RA.Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
IAC: Participated in this study as a sub-investigator and wrote the manuscript.
HB, CC, YL, WTC, YEP, YJL, YP, JL, SL, WY, JS, SWK, HAK: Participated in this study
as principle investigators at each center, reviewed the article, and provided
substantive suggestions for revision. YWS: Participated in this study as a
principle investigator, reviewed the article, and provided substantive
suggestions for revision. All authors read and approved the final manuscript.
Acknowledgements
The authors would like to thank all physicians who participated in the study.
Daewon Pharm. (Seoul, Korea) provided investigational medications for the
study, and supported the conduct of the trial. The funders played no role in the
study design, data collection or analysis, decision to publish, or preparation of
the manuscript.
Clinical research organization involved in this study was DreamCIS, Inc.
Author details
1Division of Rheumatology, Department of Internal Medicine, Seoul National
University Hospital, 101 Daehak-ro, 110-744 Jongno-gu, Seoul, South Korea.
2Division of Rheumatology, Department of Internal Medicine, Gachon
Medical School Gil Medical Center, Incheon, Korea. 3Division of
Rheumatology, Department of Internal Medicine, Yeouido St. Mary's Hospital
Catholic University Medical College, Seoul, Korea. 4Division of Rheumatology,
Department of Internal Medicine, Kyung-Hee University Medical Center,
Seoul, Korea. 5Division of Rheumatology, Department of Internal Medicine,
Dong-A University Hospital, Pusan, Korea. 6Division of Rheumatology,
Department of Internal Medicine, Pusan National University Hospital, Pusan,
Korea. 7Division of Rheumatology, Department of Internal Medicine, Seoul
National University Bundang Hospital, Seongnam, Korea. 8Division of
Rheumatology, Department of Internal Medicine, Severance Hospital, Seoul,
Korea. 9Division of Rheumatology, Department of Internal Medicine, Ewha
Women's University Mokdong Hospital, Seoul, Korea. 10Division of
Rheumatology, Department of Internal Medicine, Chonnam, National
University Hospital, Gwangju, Korea. 11Division of Rheumatology, Department
of Internal Medicine, Chonbuk National University Hospital, Jeonju, Korea.
12Division of Rheumatology, Department of Internal Medicine, Chung-Ang
University Hospital, Seoul, Korea. 13Division of Rheumatology, Department of
Internal Medicine, Chungnam National University Hospital, Daejeon, Korea.
14Division of Rheumatology, Department of Internal Medicine, Hallym
University Sacred Heart Hospital, Anyang, Korea. 15Department of Molecular
Medicine and Biopharmaceutical Sciences, Graduate School of Convergence
Science and Technology, and College of Medicine, Medical Research Center,
Seoul National University, Seoul, Korea.
Received: 31 March 2014 Accepted: 28 October 2014
Published: 18 November 2014
Reference
1. Wolfe MM, Lichtenstein DR, Singh G: Gastrointestinal toxicity of
nonsteroidal antiinflammatory drugs. N Engl J Med 1999, 340:1888–1899.
2. Schaffer D, Florin T, Eagle C, Marschner I, Singh G, Grobler M, Fenn C,
Schou M, Curnow KM: Risk of serious NSAID-related gastrointestinal
events during long-term exposure: a systematic review. Med J Aust 2006,
185:501–506.
3. Goldstein JL, Correa P, Zhao WW, Burr AM, Hubbard RC, Verburg KM, Geis
GS: Reduced incidence of gastroduodenal ulcers with celecoxib, a novel
cyclooxygenase-2 inhibitor, compared to naproxen in patients with
arthritis. Am J Gastroenterol 2001, 96:1019–1027.
4. Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, Isakson PC,
Verburg KM, Yu SS, Zhao WW, Geis GS: Anti-inflammatory and upper
gastrointestinal effects of celecoxib in rheumatoid arthritis. A randomized
controlled trial. JAMA 1999, 282:1921–1928.
5. Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H, Verburg KM,
Isakson PC, Hubbard RC, Geis GS: Celecoxib versus diclofenac in long
term management of rheumatoid arthritis: Randomized double-blind
comparison. Lancet 1999, 354:2106–2111.
6. Shin JS, Baek SR, Sohn SI, Cho YW, Lee KT: Anti-inflammatory effect of
pelubiprofen, 2-[4-(oxocyclohexylidenemethyl)-phenyl]propionic acid,
Choi et al. BMC Musculoskeletal Disorders 2014, 15:375 Page 9 of 9
http://www.biomedcentral.com/1471-2474/15/375mediated by dual suppression of COX activity and LPS-induced
inflammatory gene expression via NF-κB inactivation. J Cell Biochem 2011,
112:3594–3603.
7. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey
LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr, Mitchell DM, Neustadt
DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG: The American
Rheumatism Association 1987 revised criteria for the classification of
rheumatoid arthritis. Arthritis Rheum 1988, 31:315–324.
8. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F: The
American College of Rheumatology 1991 revised criteria for the
classification of global functional status in rheumatoid arthritis.
Arthritis Rheum 1992, 35:498–502.
9. Gillian AH, Samra M, Tetyana K, Melissa F: Measures of adult pain.
Arthritis Care Res 2011, 63(Suppl 11):s240–s252.
10. Krishnan E, Tugwell P, Fries JF: Percentile benchmarks in patients with
rheumatoid arthritis: Health assessment questionnaire as a quality
indicator (QI). Arthritis Res Ther 2004, 6:505–513.
11. Bruce B, Fries JF: The health assessment questionnaire (HAQ). Clin Exp
Rheumatol 2005, 23(Suppl 39):514–518.
12. International Conference on Harmonization of Technical Requirements for
Registration of Pharmaceuticals for Human Use. Note for guidance on Clinical
Safety Data Management: Definitions and Standards for Expedited Reporting
E2A. Current Step 4 version dated 27 October 1994. Available at http://www.
ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2A/
Step4/E2A_Guideline.pdf.
13. Song YW, Lee EY, Koh EM, Cha HS, Yoo B, Lee CK, Baek HJ, Kim HA, Suh YI,
Kang SW, Lee YJ, Jung HG: Assessment of comparative pain relief and
tolerability of SKI306X compared with celecoxib in patients with
rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind,
double-dummy, phase III, noninferiority clinical trial. Clin Ther 2007,
29:862–873.
14. Shin BJ, Kim TK, Baik JS, Shim DM: Comparison the safety and the efficacy
between the group of using pelubiprofen tab. and the group of using
aceclofenac tab. on back pain patients – Multi-institution, double blind,
random sample. J Korean Soc Spine Surg 2012, 19:38–46.
15. Scott PA, Kingsley GH, Smith CM, Choy EH, Scott DL: Nonsteroidal
anti-inflammatory drugs and myocardial infarctions: comparative
systematic review of evidence from observational studies and
randomized controlled trials. Ann Rheum Dis 2007, 66:1296–1304.
doi:10.1186/1471-2474-15-375
Cite this article as: Choi et al.: Comparison of the efficacy and safety
profiles of a pelubiprofen versus celecoxib in patients with rheumatoid
arthritis: a 6-week, multicenter, randomized, double-blind, phase III,
non-inferiority clinical trial. BMC Musculoskeletal Disorders 2014 15:375.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
